Polar Asset Management Partners’s BioMarin Pharmaceuticals BMRN Stock Holding History

Polar Asset Management Partners’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-14,900	Closed	-$979K	–	567
2024 Q4	$979K	Buy	+14,900	New	+$998K	0.01%	442
2024 Q3	–	Sell	-50,000	Closed	-$4.12M	–	733
2024 Q2	$4.12M	Sell	50,000 -5,000	-9%	-$416K	0.09%	226
2024 Q1	$4.8M	Sell	55,000 -29,600	-35%	-$2.65M	0.08%	218
2023 Q4	$8.16M	Buy	+84,600	New	+$7.48M	0.14%	142

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

EIM

Elliott Investment Management West Palm Beach, Florida $20.1B AUM 60.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Polar Asset Management Partners's BMRN Position: Q1 2025 in Review

Polar Asset Management Partners sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2025, closing a stake of 14,900 shares — an estimated $979K sold.

Polar Asset Management Partners first reported a position in BMRN in Q4 2023 and held it in 4 quarters. The position peaked at $8.16M in Q4 2023. 584 funds tracked by Wall St. Rank hold BMRN as of Q1 2025.

Polar Asset Management Partners reported no remaining BioMarin Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
Polar Asset Management Partners sold 14,900 BioMarin Pharmaceuticals shares in Q1 2025, an estimated $979K.
Polar Asset Management Partners first reported a position in BioMarin Pharmaceuticals in Q4 2023 and held it in 4 quarters.
Polar Asset Management Partners's BioMarin Pharmaceuticals position peaked at $8.16M in Q4 2023.
584 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2025.

Based on Polar Asset Management Partners's 13F filing for Q1 2025, filed 15 May 2025.